Nature Reviews Neurology

Article	Citations
Lymphatic propagation of α-synuclein	518
Microglia, spreaders of Aβ seeds	313
Transmembrane protein interacts with α-synuclein to confer risk of PD	303
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	291
Ventricular enlargement caused by aducanumab	281
Brain stimulation aids walking after spinal injury	246
Refining oxytocin therapy for autism: context is key	242
Reply to ‘Perils and pitfalls of near-death experience research’	216
Global synergistic actions to improve brain health for human development	214
Neural cell state shifts and fate loss in ageing and age-related diseases	214
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	212
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	208
NODDI reveals brain microstructural changes in multiple sclerosis	202
Disease-specific modifications of tau protein	186
Continuous levodopa production by an artificial enzyme	185
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	179
Spinal muscular atrophy treatment in utero	174
Nir Giladi (1955–2024)	171
SEQUINS — a new initiative to address disparities in neurology	149
The impact of rare genetic variants on Alzheimer disease	142
The Digitized Memory Clinic	136
Mitochondrial DNA instability in Huntington disease	136
Study reveals new ALS risk genes	135
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	128
TREM2 mediates phagocytosis in glioblastoma	126

Microglia subset associated with high-grade glioma	125
Imperatives and co-benefits of research into climate change and neurological disease	120
The role of the gut microbiota in multiple sclerosis	115
Ultrasound lets gene therapy into the brain	108
Brain volume is associated with cognition in MS	107
Role for endogenous retrovirus in FTD	106
Amyloid plaques: hotspots for microglial turnover	104
Menopause influences tau pathology	104
Neurological care for LGBT+ people	103
Implications of AD plasma and PET biomarker discordance	102
Neuroinflammation predicts cognitive decline in FTD	100
Psychosis-causing lesions mapped to a hippocampal circuit	97
The challenges of anti-tau therapeutics in Alzheimer disease	96
MRI-based deep learning for TLE diagnosis	94
Diversity, equity and inclusion in neurology	93
Brain imaging illuminates cognitive impairment in multiple sclerosis	93
Author Correction: Viral pathogens increase risk of neurodegenerative disease	86
Parkinson disease pathology can originate in the kidney	85
First trials test targeting of α-synuclein for Parkinson disease	85
Gene therapy for seizures in focal cortical dysplasia	84
Precision neuroimmunology in multiple sclerosis — the horizon is near	83
α-Synuclein pathology as a target in neurodegenerative diseases	80
Management of freezing of gait — mechanism-based practical recommendations	80
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	77
APOE ε4 influences Parkinson disease progression	75
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	74
Challenges of combining multimodal data in assessment of people with traumatic brain injury	72
Evidence for altered astrocyte function in Duchenne muscular dystrophy	71
Food is brain medicine — relevance and translation to neurology	71
Neurosteroids alleviate seizures in rats	70
Glymphatic dysfunction in PD clinical progression	68
A new biological classification for Parkinson disease	66
Thalamic inflammation — a therapeutic target for brain injury?	66
Exosomal microRNA is promising biomarker in PD	64
Addressing disparities in neurology by building the workforce in LMICs	61
Ultrasound ablation treatment for PD	60
Coeliac disease as a model for understanding multiple sclerosis	59
Spinal cord stimulation for the treatment of chronic pain	59
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	58
New IDEAS about amyloid, race and dementia disparities	56
Apparent changes in the epidemiology and severity of multiple sclerosis	55
The global and regional burden of diabetic peripheral neuropathy	54
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	53
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	52
Is Alzheimer disease a disease?	52
The role of glial cells in multiple sclerosis disease progression	50
Synaptic degeneration in Alzheimer disease	50
From the prodromal stage of multiple sclerosis to disease prevention	50
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	48
Hypothalamus loses control in migraine	47

Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	47
Oligomeric tau could spread through synapses in AD	45
Hypothyroidism is associated with dementia risk	44
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	44
X-chromosome variants and PD in Latin America	44
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	44
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	43
Neurofilament light chain induces neuroinflammation	43
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	42
Global epidemiology of migraine and its implications for public health and health policy	41
Cognitive impairment and World Trade Centre-related exposures	41
The inter-relationship between delirium and dementia: the importance of delirium prevention	40
Dual function of biomolecular condensates	38
Moving towards meaningful patient and public engagement	38
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	38
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	38
Risk locus for paediatric astrocytoma identified	37
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	36
Change in stroke outcomes over 20 years	36
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	36
α-Synuclein seeds in amyotrophic lateral sclerosis	36
Prognostic plasma biomarkers for spinal cord injury	35
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	35
CAR T cells offer hope in glioblastoma	34
Huntington disease-like 2: insight into neurodegeneration from an African disease	33
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	33
New developments in guidelines for brain death/death by neurological criteria	32
Origins and immunopathogenesis of autoimmune central nervous system disorders	31
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	31
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	31
Positron emission tomography in multiple sclerosis — straight to the target	31
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	29
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	25
High rate of epilepsy in young individuals who died with COVID-19	24
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Charting brain development across the human lifespan	24
Neurogenesis altered in multiple neurodegenerative diseases	24
Serum NfL as an MS biomarker	24
Deep learning distinguishes tauopathies	24
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	24
Does antiherpetic antiviral therapy reduce the risk of dementia?	23
AI and protein structure and function in neurological disease: relevance to disease management	21
John Q. Trojanowski	21
Aberrant protein networks in Alzheimer disease	20
ALS pathogenesis linked to actin barrier collapse	20
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	19
BCAS1+ oligodendrocytes aid remyelination in MS	19
Author Correction: The complex aetiology of cerebral palsy	19
Pharmacological rehabilitation for stroke	19
AI aces diagnosis of chronic ataxias	18
The murky waters of sex differences in post-stroke cognitive impairment	17
Pathogenetic mechanisms and treatment targets in cerebral malaria	17
Neuroprognostication: a conceptual framework	17
Alzheimer disease in African American individuals: increased incidence or not enough data?	16
Addressing disparities in the global epidemiology of stroke	16
Molecular biomarkers for vascular cognitive impairment and dementia	14
Genome-wide analysis furthers decoding of Alzheimer disease genetics	14
Nusinersen treatment response markers	13
Effects of diet on MS onset and course	13
Clocking the age of Parkinson disease onset	13
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	12
Altered muscle cholesterol transport in ALS	12
Predictive tools in psychosis: what is ‘good enough’?	12
Nanoprobe for blood–brain barrier changes	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Alzheimer disease seen through the lens of sex and gender	11
Multidimensional MRI detects astrogliosis	11
Mechanistic insights into the interaction between epilepsy and sleep	11
Seizure-associated changes in the Golgi apparatus	11
Advancing multiple sclerosis management in older adults	11
Markers help to predict dementia with Lewy bodies	11
Sex and gender in neurodevelopmental conditions	11
Parkinson disease pathology in inflammatory bowel disease	10
Shared glial pathology in HD and schizophrenia	10
Multisite chronic pain: a risk factor for dementia	10
Evidence-based clinical care and policy making for schizophrenia	10
The missing X factor in Alzheimer disease	9
Advances in the therapeutic algorithm for myasthenia gravis	9

Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	9
Alzheimer disease in Down syndrome linked to APOE	9
Walking the Talk for Dementia — an experience to break down barriers	8
Psychiatric sequelae of traumatic brain injury — future directions in research	8
Immune mechanisms and shared immune targets in neurodegenerative diseases	8
Limitations of neurocentric models for near-death experiences	8
Inclusion in neurological research: empowering people living with neurological diseases	8
Novel oxytocin spray is beneficial in ASD	8
Artificial intelligence in epilepsy — applications and pathways to the clinic	8
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	8
Author Correction: Why functional neurological disorder is not feigning or malingering	8
A global view of the genetic basis of Alzheimer disease	8
Glymphatic dysfunction detected in bvFTD	7
Identification of neurons involved in schizophrenia	7
Review and update of the concept of embolic stroke of undetermined source	7
T cell–microbiome communication influences disease in MS model	7
Ageing reduces potential for remyelination in multiple sclerosis	7
Sensory feedback in upper limb prosthetics: advances and challenges	7
MS drug beneficial in an underrepresented group	7
Recycling brain scans with AI	7
PD pathology spread linked to mtDNA damage	7
Peripheral B cells altered in Parkinson disease	7
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	7
Vulnerable dopamine neurons identified	7
Early-stage Alzheimer disease: getting trial-ready	6
Dementia risk scores in diverse populations	6
Multifaceted roles of APOE in Alzheimer disease	6
Astrocytes in the initiation and progression of epilepsy	6
Calcium dysregulation could underlie lysosomal impairment in AD	6
BTK inhibitor falters in multiple sclerosis trials	6
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	6
Oestrogen receptor variants linked to AD traits	6
Functional brain networks in the evaluation of patients with neurodegenerative disorders	6
Breakthrough technology restores function after complete paralysis	6
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	6
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	6
Addressing disparities in neurology by enhancing inclusive practice	5
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	5
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	5
Microglial senescence is a potential therapeutic target for Alzheimer disease	5
Monitoring disease onset in amyotrophic lateral sclerosis	5
Translating lifestyle interventions for optimal brain health in Africa	5
Stem cells show promise in Parkinson disease	5
Engineered TREM2 antibody clears Aβ in mice	5
Oligodendrocyte progenitor cell transplant for MS	5
EBV-specific T cells in multiple sclerosis	5
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	5
From precision diagnosis to precision treatment in epilepsy	5
Implications of immunometabolism for smouldering MS pathology and therapy	5
Brain–machine interface treats pain in rats	5
Publisher Correction: Microglial transcriptomics meets genetics: new disease leads	5
Closing the loop for patients with Parkinson disease: where are we?	4
Skin α-synuclein differentiates synucleinopathies	4
Identifying molecular targets in trigeminal nociception	4
Addressing disparities in neurology by identifying gaps in hospital care	4
Novel plasma markers for Parkinson disease	4
Sleep and circadian disturbances in children with neurodevelopmental disorders	4
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder	4
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	4
A biomarker for mild cognitive impairment	4
Insights into the toxic effects of mutant huntingtin	4
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	4
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	4
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
GluA2 modulator targets excitotoxicity in MS	4
New CRISPR-based strategies for Alzheimer disease	4
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	4
New local therapy strategies for brain tumours	3
WNT receptor variant linked to synaptic degeneration	3
Exosomal microRNAs may aid differential diagnosis of movement disorders	3
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	3
Epigenetic clocks and DNA methylation biomarkers of brain health and disease	3
White matter hyperintensities — location matters	3
Pro-inflammatory diet is linked to dementia risk	3
Why functional neurological disorder is not feigning or malingering	3
Spreading depolarization as a therapeutic target in migraine	3
Early-onset dementia in autism spectrum disorder	3
Exome sequencing identifies risk variants for AD	3
Finger-prick blood test for Alzheimer disease	3
Glioblastoma tackled with oncolytic virus	3
Lecanemab trial in AD brings hope but requires greater clarity	3
FSH provides link between menopause and AD	3
MS drug alters B cell metabolism	3
Stroke in Africa: profile, progress, prospects and priorities	3
Autoimmune encephalitis-associated epilepsy	3
The importance of getting evidence into practice	3
Levosimendan fails to improve respiratory function in amyotrophic lateral sclerosis	3
Disentangling clinical and biological trajectories of neurodegenerative diseases	3
‘On-demand’ gene therapy for epilepsy	3
Bruton tyrosine kinase inhibitors for multiple sclerosis	3
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	3
A tale of race and B cells in multiple sclerosis	3
Epstein–Barr virus and MS — a causal link	3
Environmental–genetic interactions in ageing and dementia across Latin America	3